H2 cleavage at th...Figure 4.11 Possible proton pathways to the H‐cluster involving amino‐acid r...Figure 4.12 Amino‐acid network surrounding the 2FeH subcluster for the CpIAD...Figure 4.13 [FeFe]‐hydrogenase model complexes that produce H2.Figure 4.14 Proposed [Fe]‐hydrogenase catalytic cycle.Figure 4.15 [Fe]‐hydrogenase model compounds: (a) short‐lived model compound...Figure 4.16 Human carbonic anhydrase II (hCAII), PDB 1CA2.Figure 4.17 Hydrophilic water channel leading to the Zn2+ active site and hy...Figure 4.18 Methazolamide interaction at the hCA II active site PDB 5C8I [34...Figure 4.19 Trifluoro hydroxamate hCA II inhibitor at the active site PDB 1A...Figure 4.20 The nitrogen cycle.Figure 4.21 iNOS active site with substrate L‐arginine from PDB 1NOD [48].Figure 4.22 PDB 1M8D iNOSox with inhibitor chlorzoxazone from reference [44]...Figure 4.23 Inducible NOS inhibitors from reference [49].Figure 4.24 L‐arginine and amidine inactivators of iNOS from reference [45]....Figure 4.25 PDB 5VV5 active site of hnNOS with inhibitor bound [51].Figure 4.26 Siroheme‐[4Fe4S] cluster active site for CSNIR nitrite reductase...Figure 4.27 Hemes and types I and II copper centers found in various NO enzy...Figure 4.28 Cd1NIR nitrite reductase visualized from PDB 1NIR [54].Figure 4.29 Type I and type II copper sites for the nitrite reductase enzyme...Figure 4.30 Copper complex catalyzing the reaction forming NO from nitrite i...Figure 4.31 Route 2 mechanism for NO(g) release in CuNIR nitrite reductase [...Figure 4.32 CuNIR model complexes studied in reference [60].Figure 4.33 Model complexes and reactions with NO(g) [64].5 Chapter 5Figure 5.1 Reconfigurable DNA tripods (a) tripod design: each arm consists o...Figure 5.2 (a) An ssDNA scaffold hybridizes with staple and capture strands ...Figure 5.3 Three major motifs for building two‐ and three‐dimensional DNA na...Figure 5.4 Scaffold (long ssDNA) and staple (short ssDNA) used to create nan...Figure 5.5 (a) Biotin and (b) streptavidin as connectors for nucleic acids t...Figure 5.6 Response of a gold nanorod‐DNA origami template nanostructure to ...Figure 5.7 Sizes and shapes of some important nanomaterials and other matter...Figure 5.8 Formation of a hybrid nanogel system.Figure 5.9 (a) Sizes, shapes, and surface‐functionalized nanoparticles targe...Figure 5.10 Functionalizing ligands for inorganic nanoparticles.Figure 5.11 Anticancer agents delivered in single‐ and multi‐wall carbon nan...
6 Chapter 6Figure 6.1 Structures of platinum anticancer agents approved for clinical us...Figure 6.2 Platinum(II) compounds approved for use outside the United States...Figure 6.3 An antitumor active trans‐platinum(II) compounds BBR3464 (Triplat...Figure 6.4 Dickerson Dodecamer (DDD) in complex with Triplatin indicating ph...Figure 6.5 Disaccharide linkages in heparan sulfate (HS).Figure 6.6 (a) Phosphate clamp; (b) sulfate clamp; (c) phosphate–arginine fo...Figure 6.7 Antitumor drugs used in combination with platinum‐containing anti...Figure 6.8 The anticancer platinum(IV) prodrug mitaplatin.Figure 6.9 (a) Formation of the metal‐organic cage (MOC) (b) formation of th...Figure 6.10 Ruthenium(III) antitumor compounds NAMI‐A, KP1019, and NKP1339....Figure 6.11 X‐ray crystallographic structure of NAMI‐A reaction products wit...Figure 6.12 Ruthenium(II) half sandwich antitumor compounds RAED‐C and RAPTA...Figure 6.13 [RuCl2(η6‐arene)(η1‐S‐aroylthiourea)] anticancer active complexe...Figure 6.14 Cartoon representation of [RuCl2(η6‐arene)(η1‐S‐aroylthiourea)] ...Figure 6.15 Comparison of activity of Ir and Ru half‐sandwich complexes.Figure 6.16 (a) Ruthenium(II) and (b) Iridium(II) antitumor complexes.Figure 6.17 Ruthenium(II) and osmium(II) antitumor complexes.Figure 6.18 Osmium(II) antitumor complexesFigure 6.19 Gold and titanium antitumor compounds.Figure 6.20 Copper complexes in clinical trials.Figure 6.21 Bismuth drugs and drug components.Figure 6.22 Colloidal bismuth subcitrate (CBS).Figure 6.23 (a) Structure Cu‐only SodC from Mycobacterium tuberculosis, (b) ...Figure 6.24 Superoxide dismutase variants found in prokaryotic bacteria and ...Figure 6.25 MnSOD2 in Homo sapiens susceptible to nitration inactivation and...Figure 6.26 Drugs used in ALS treatment.Figure 6.27 X‐ray structures of ALS mutants. (a) Metal‐reconstituted CuZn SO...Figure 6.28 Riluzole and active riluzole‐triazole hybrid compounds.Figure 6.29 Drugs or potential drugs used in Menkes disease treatment.Figure 6.30 Drugs or potential drugs used in Wilson disease treatment.Figure 6.31 (a) Aβ1–42 peptide dimer determined by cryo‐electron micro...Figure 6.32 Metal coordination spheres for (a) Cu(I)–Aβ peptide; (b) Cu(II)–...Figure 6.33 (a) copper chelator PBT2; (b) copper chelator gtsm; (c) copper c...Figure 6.34 Drugs used combination therapy with arsenic trioxide for treatme...Figure 6.35 (a–d) Vanadium compounds used in type 2 diabetes treatment; (e, ...
Guide
1 Cover
2 Table of Contents
Pages
1 iii
2 iv
3 v
4 xiii
5 xiv
6 xv
7 xvii
8 xix
9 xxi
10 xxii
11 1
12 2
13 3
14 4
15 5
16 6
17 7
18 8
19 9
20 10
21 11
